News & Updates
Filter by Specialty:
3-month rivaroxaban use safe, effective in isolated DVT
Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.
3-month rivaroxaban use safe, effective in isolated DVT
01 Dec 2022
Intensive antihypertensive therapy vital in kids with arterial hypertension after CoA repair
Close blood pressure (BP) monitoring and more intensive and combined antihypertensive therapy are needed when there is a high prevalence of uncontrolled arterial hypertension (AH) despite the successful coarctation of the aorta (CoA) correction and use of relatively low doses of antihypertensive drugs, suggests a recent study.
Intensive antihypertensive therapy vital in kids with arterial hypertension after CoA repair
30 Nov 2022
Vilobelimab augments treatment armamentarium for critically ill COVID-19 patients
In the phase III part of the PANAMO trial, the anti-C5a monoclonal antibody vilobelimab, when added to standard of care (SoC), improved survival in COVID-19 patients who required invasive mechanical ventilation (IMV).
Vilobelimab augments treatment armamentarium for critically ill COVID-19 patients
29 Nov 2022
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
Alprazolam safe, effective for controlling seizures
The use of alprazolam leads to rapid termination of seizures in patients with focal and/or generalized epilepsy treated in an inpatient setting, according to the results of the phase II study ENGAGE-E-001.